Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
J. Clin. Invest. Vinayakumar Siragam, et al. 115:155 doi:10.1172/JCI22753 [Go to this article.]

Figure 5
FcγRIIB expression is not required for reversal of ITP by OVA-rbcs + anti-OVA. Control (C57BL/6) mice (A) or FcγRIIB^–/– mice (B) were injected with 2 μg anti-platelet antibody on days 0 through 3 (upward-pointing arrows). On day 2 (downward-pointing arrows) mice were injected intraperitoneally with 50 mg IVIg (open squares) or intravenously with OVA-rbcs + anti-OVA (open triangles) or OVA-rbcs + control IgG (filled triangles). Platelet counting was as described in Figure 4; n = 5 mice for each group from 5 independent experiments. ^#P < 0.001 vs. OVA-rbcs alone. Data are presented as mean ± SEM.